Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) had its price objective raised by Stifel Nicolaus from $42.00 to $50.00 in a research note published on Wednesday, MarketBeat.com reports. Stifel Nicolaus currently has a hold rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Ionis Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. Sanford C. Bernstein assumed coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, July 27th. They issued a market perform rating and a $57.00 price target for the company. Needham & Company LLC reaffirmed a buy rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. BMO Capital Markets reaffirmed an outperform rating and issued a $62.00 price target (up previously from $59.56) on shares of Ionis Pharmaceuticals in a research report on Tuesday, July 25th. Finally, TheStreet raised shares of Ionis Pharmaceuticals from a d+ rating to a c- rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals has a consensus rating of Hold and a consensus price target of $47.13.

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded up 2.63% during mid-day trading on Wednesday, reaching $46.76. 2,627,979 shares of the company’s stock traded hands. Ionis Pharmaceuticals has a 12-month low of $24.58 and a 12-month high of $60.01. The firm has a market capitalization of $5.81 billion, a price-to-earnings ratio of 224.81 and a beta of 3.14. The stock has a 50-day moving average price of $52.52 and a 200 day moving average price of $46.92.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same period in the previous year, the company posted ($0.47) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% on a year-over-year basis. Analysts anticipate that Ionis Pharmaceuticals will post ($0.02) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Price Target Raised to $50.00” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/08/12/ionis-pharmaceuticals-inc-ions-price-target-raised-to-50-00.html.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $59.29, for a total transaction of $592,900.00. Following the transaction, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $55.35, for a total transaction of $608,850.00. Following the transaction, the chairman now owns 48,014 shares in the company, valued at approximately $2,657,574.90. The disclosure for this sale can be found here. Insiders have sold 54,379 shares of company stock valued at $2,946,052 in the last three months. 1.86% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of IONS. Dimensional Fund Advisors LP raised its position in shares of Ionis Pharmaceuticals by 361.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 97,341 shares of the company’s stock worth $4,656,000 after buying an additional 76,259 shares during the last quarter. Teachers Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 14.7% in the fourth quarter. Teachers Advisors LLC now owns 123,810 shares of the company’s stock worth $5,922,000 after buying an additional 15,904 shares during the last quarter. Raymond James Trust N.A. raised its position in shares of Ionis Pharmaceuticals by 2.9% in the first quarter. Raymond James Trust N.A. now owns 5,705 shares of the company’s stock worth $229,000 after buying an additional 159 shares during the last quarter. Creative Planning raised its position in shares of Ionis Pharmaceuticals by 5.7% in the first quarter. Creative Planning now owns 26,856 shares of the company’s stock worth $1,080,000 after buying an additional 1,442 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.